Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-26-056595
Filing Date
2026-05-14
Accepted
2026-05-14 16:05:36
Documents
75
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0289477-10q_jasper.htm   iXBRL 10-Q 770482
2 CERTIFICATION ea028947701ex31-1.htm EX-31.1 11226
3 CERTIFICATION ea028947701ex31-2.htm EX-31.2 11100
4 CERTIFICATION ea028947701ex32-1.htm EX-32.1 7351
  Complete submission text file 0001213900-26-056595.txt   5019343

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE jspr-20260331.xsd EX-101.SCH 55047
6 XBRL CALCULATION FILE jspr-20260331_cal.xml EX-101.CAL 33143
7 XBRL DEFINITION FILE jspr-20260331_def.xml EX-101.DEF 182754
8 XBRL LABEL FILE jspr-20260331_lab.xml EX-101.LAB 379143
9 XBRL PRESENTATION FILE jspr-20260331_pre.xml EX-101.PRE 303982
79 EXTRACTED XBRL INSTANCE DOCUMENT ea0289477-10q_jasper_htm.xml XML 556197
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

EIN.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39138 | Film No.: 26978754
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)